Menu

Pfizer Inc. PFE

Full chart Compare
Set alert

Price alert · PFE

All alert types
29.88 USD -0.91 (-2.96%)

At closeNov 5, 2026, 7:57 PM EST

29.90 +0.02 +0.07%

After hours · Nov 5, 7:57 PM ET

29.85 Day range 31.44
23.67 52-week range 30.79
YTD
+20.00%
1 year
+21.41%
Market cap
170.31B
Revenue (ttm)
63.62B
Profit margin
6.34%
EPS (ttm)
0.68
Shares out
5.70B
P/E ratio
43.94
Forward P/E
10.58
Dividend
1.72 (5.73%)
Ex-dividend date
Nov 5, 2026
YTD return
+20.00%
1-year return
+21.41%
Volume
52.81M
Avg volume
33.82M
Open
31.09
Previous close
30.79
Day's range
29.85 – 31.44
52-week range
23.67 – 30.79
Analysts
Buy
Price target
29.45 (-1.4%)
Earnings date
Feb 2, 2027

5D -0.67 (-2.19%)

3030.503131.50FriMonTueWedThu29.88

Key statistics

Enterprise value
0
PEG ratio
13.75
Price / sales
2.76
Price / book
2.02
Dividend yield
5.73%
Payout ratio
245.71%
Revenue growth
-0.40%
Free cash flow
0
Total cash
0
Total debt
0
Return on equity
0.00%
Short % of float
2.42%
50-day average
28.64
200-day average
26.84

Financials — quick view

All financials
PFE Revenue — quarterly 16.58B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PFE Net income — quarterly 3.24B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PFE EPS — quarterly 0.57
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

PFE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 27, 20260.72———
Nov 3, 2026Sep 27, 20260.7350.87+0.14+18.37%
Aug 4, 2026Jun 28, 20260.6820.77+0.09+12.90%
May 5, 2026Mar 29, 20260.7220.75+0.03+3.88%
Feb 3, 2026Dec 31, 20250.5670.66+0.09+16.40%
Nov 4, 2025Sep 28, 20250.6330.87+0.24+37.44%

Upgrades / downgrades

PFE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026RBC CapitalmainSector PerformSector Perform
Oct 9, 2026JP MorganmainNeutralNeutral
Oct 8, 2026Cantor FitzgeraldmainNeutralNeutral
Oct 6, 2026ScotiabankmainSector OutperformSector Outperform
Sep 10, 2026HSBCmainHoldHold
Aug 7, 2026GuggenheimmainBuyBuy

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
pfizer.com

News

Your note

Sign in to keep a note on PFE — it syncs with the Stock Master app.

Institution ownership

PFE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.29%529,670,43316.31BJun 29, 2026
Vanguard Capital Management LLC6.53%372,149,85211.46BJun 29, 2026
State Street Corporation5.39%307,090,8979.46BJun 29, 2026
Geode Capital Management, LLC2.37%135,275,7824.17BJun 29, 2026
Vanguard Portfolio Management LLC2.09%119,235,0303.67BJun 29, 2026
Fisher Asset Management, LLC1.91%109,067,2913.36BJun 29, 2026

Fund ownership

PFE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%180,944,8985.57BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%147,700,0664.55BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%75,946,8892.34BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%74,072,7172.28BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%70,581,6112.17BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Value Index Fund0.95%54,248,0961.67BJun 29, 2026